Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response

Saved in:

Bibliographic Details
Published in:	American journal of hematology Vol. 95; no. 12; pp. E321 - E323
Main Authors:	Pagnano, Katia B.B., Lopes, Ana Beatriz P., Miranda, Eliana C., Delamain, Márcia T., Duarte, Gislaine O., Rodrigues, Bruna R.V., Povoa, Valquiria M.O., Furlin, Graziele C.P., Vianna, Jessica C., Silva, Matheus A.S., De Souza, Carmino A, De Paula, Erich V
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 01-12-2020 Wiley Subscription Services, Inc
Subjects:	Chronic myeloid leukemia Hematology Imatinib Myeloid leukemia Pioglitazone Targeted cancer therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	Funding information Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Grant/Award Number: 88882.434900/2019‐01 SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Feature-1 ObjectType-Correspondence-3
ISSN:	0361-8609 1096-8652
DOI:	10.1002/ajh.25986